Send to

Choose Destination
Sci Rep. 2016 Mar 2;6:22525. doi: 10.1038/srep22525.

Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease.

Feng Q1,2,3, Liu Z1,4, Zhong S5,6, Li R7, Xia H1,8, Jie Z1,8, Wen B1, Chen X1, Yan W7, Fan Y1, Guo Z1, Meng N1,8, Chen J5, Yu X5,6, Zhang Z6, Kristiansen K1,9, Wang J1,9,10,11,12, Xu X1, He K7, Li G1.

Author information

BGI-Shenzhen, Shenzhen, 518083, China.
Department of Oral Microbiome, School of Stomatology, Shandong University, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, China.
Shenzhen Engineering Laboratory of Detection and Intervention of human intestinal microbiome.
College of Life Sciences, University of Chinese Academy of Sciences, 19A Yuquan Road, Shijingshan District, Beijing, 100094, China.
Medical Research Center of Guangdong General Hospital, Guangzhou, Guangdong, China.
Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Department of cardiology, Chinese PLA general hospital, Fuxing Road 28, Beijing, 100853, China.
Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen, China.
Department of Biology, University of Copenhagen, Ole MaaløesVej 5, 2200 Copenhagen, Denmark.
Princess Al Jawhara Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Macau University of Science and Technology, Avenida Wai long, Taipa, Macau 999078, China.
Department of Medicine, University of Hong Kong, Hong Kong.


Coronary heart disease (CHD) is top risk factor for health in modern society, causing high mortality rate each year. However, there is no reliable way for early diagnosis and prevention of CHD so far. So study the mechanism of CHD and development of novel biomarkers is urgently needed. In this study, metabolomics and metagenomics technology are applied to discover new biomarkers from plasma and urine of 59 CHD patients and 43 healthy controls and trace their origin. We identify GlcNAc-6-P which has good diagnostic capability and can be used as potential biomarkers for CHD, together with mannitol and 15 plasma cholines. These identified metabolites show significant correlations with clinical biochemical indexes. Meanwhile, GlcNAc-6-P and mannitol are potential metabolites originated from intestinal microbiota. Association analysis on species and function levels between intestinal microbes and metabolites suggest a close correlation between Clostridium sp. HGF2 and GlcNAc-6-P, Clostridium sp. HGF2, Streptococcus sp. M143, Streptococcus sp. M334 and mannitol. These suggest the metabolic abnormality is significant and gut microbiota dysbiosis happens in CHD patients.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center